

Curriculum Vitae

Benjamin Ostendorf

Department of Hematology, Oncology
and Tumor Immunology
Charité Universitätsmedizin
Augustenburger Platz 1 | 13353 Berlin | Germany
+49 30 450 653 605
benjamin.ostendorf@charite.de
www.ostendorflab.org

Current positions

- 05/2022 – present **Affiliated group leader**, *Berlin Institute for Medical Systems Biology (BIMBS), Max Delbrück Center, Berlin*, Berlin, Germany
- 04/2022 – present **Faculty member**, *Berlin School of Integrative Oncology*, Berlin, Germany
- 01/2022 – present **Group Leader and resident physician**, *Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin*, Berlin, Germany
- since 06/2022 Max Eder program of the German Cancer Aid

Previous positions

- 06/2015 – 12/2021 **Postdoctoral and graduate fellow**, *Laboratory of Systems Cancer Biology (Professor S. Tavazoie)*, *The Rockefeller University*, New York, USA
- Obtained PhD degree 07/2017 – 06/2020.
- 11/2011 – 03/2015 **Resident and research fellow**, *Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin*, Berlin, Germany

Education and key qualifications

- 03/2024 **Board certification for Internal Medicine**
- 11/2023 **Habilitation & Venia legendi in Experimental Oncology**, *Charité Universitätsmedizin*, Berlin, Germany
- 07/2017 – 06/2020 **PhD in Systems Cancer Biology**, *The Rockefeller University, Dr. S. Tavazoie*, New York City, USA
- 01/2014 **Medical doctoral thesis**, *Albert-Ludwigs-University, Molecular Nephrology (Prof. T.B. Huber)*, Freiburg, Germany
- Grade *summa cum laude* (highest distinction).
- 10/2004 – 05/2011 **Medical studies**, *Albert-Ludwigs-University, University of South Florida, Queen Mary University and Mount Sinai School of Medicine*, Freiburg (Germany), Tampa (USA), London (UK) and New York (USA)
- Final grade 1.0.
- 08/1994 – 06/03 **High school diploma**, *Christianeum*, Hamburg, Germany
- Grade 1.0 (top of class)

Awards and Scholarships

- since 06/2022 **Max Eder program of the German Cancer Aid**, *Charité Universitätsmedizin*, Berlin, Germany
- since 01/2022 **BIH - Charité Digital Clinician Scientist program**, *Charité Universitätsmedizin*, Berlin, Germany
- 12/2018 **Helmsley Fellowship**, *The Rockefeller University*, New York, USA

- 06/2015 – 05/2017 **Postdoctoral Research Fellowship by the Deutsche Forschungsgemeinschaft (German Research Foundation)**, *Rockefeller University*, New York, USA
- 09/2008 – 05/2011 **Scholar of the German National Academic Foundation**
- 06/2003 **Prize for the best school leaving exam**, *Christianeum*, Hamburg, Germany

Memberships

- Deutsche Gesellschaft für Innere Medizin
- Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
- Association for Cancer Immunotherapy CIMT e.V.

Academic Service

Ad-hoc Reviewer

- Cell Reports Methods
- Journal of Translational Medicine
- Cell (with Dr. Tavazoie)
- Nature Communications (with Dr. Tavazoie)
- PNAS (with Dr. Tavazoie)
- JCI (with Dr. Tavazoie)
- Bone Marrow Transplantation
- Biology of Blood and Marrow Transplantation
- European Respiratory Journal

Patents

- 02/2019 ***APOE genotype in cancer prognostics***
US provisional patent 62/811,575
Ostendorf BN, Tavazoie SF

Publications

Original articles

- 2023 Adaku N, Ostendorf BN, Mei W, and Tavazoie SF (2023). *Apolipoprotein E2 stimulates protein synthesis and promotes melanoma progression and metastasis*. **Cancer Research** 83:3013–3025.
- 2022 Ostendorf BN[†], Patel MA, Bilanovic J, Hoffmann HH, Carrasco SE, Rice CM, and Tavazoie SF[†] (2022). *Common human genetic variants of APOE impact murine COVID-19 mortality*. **Nature** 611:346–351. ([†]corresponding authors)
 - Research highlight in *Nature Metabolism* 09/2022
- 2022 Moy RH, Nguyen A, Loo JM, Yamaguchi N, Kajba CM, Santhanam B, Ostendorf BN, Wu YG, Tavazoie S, and Tavazoie SF (2022). *Functional genetic screen identifies ITPR3/Calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization*. **Developmental Cell** 57:1146–1159.e7.
- 2021 Zhu XG, Chudnovskiy A, Baudrier L, Prizer B, Liu Y, Ostendorf BN, Yamaguchi N, Arab A, Tavora B, Timson R, Heissel S, de Stanchina E, Molina H, Victora GD, Goodarzi H, and Birsoy K (2021). *Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells*. **Cell Metabolism** 33:211–221.e6.
- 2020 Tavora B, Mederer T, Wessel KJ, Ruffing S, Sadjadi M, Missmahl M, Ostendorf BN, Liu X, Kim JY, Olsen O, Welm AL, Goodarzi H, and Tavazoie SF (2020). *Tumoural activation of TLR3–SLIT2 axis in endothelium drives metastasis*. **Nature** 586:299–304.

- 2020 Ostendorf BN, Bilanovic J, Adaku N, Tafreshian KN, Tavora B, Vaughan RD, and Tavazoie SF (2020). *Common germline variants of the human APOE gene modulate melanoma progression and survival.* **Nature Medicine** 26:1048–1053.
- Research highlight in *Nature Reviews Cancer* 06/2020
- 2018 Ostendorf BN[†], Flenner E, Flörcken A, and Westermann J[†] (2018). *Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.* **PLOS ONE** 13:e0197823. ([†]corresponding authors)
- 2018 Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, and Tavazoie SF (2018). *LXR/ApoE activation restricts innate immune suppression in cancer.* **Cell** 172:825–840.e18.
- Research highlight in *Nature Reviews Clinical Oncology* 01/2018 & *Nature Reviews Drug Discovery* 02/2018
- 2015 Flörcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, Dörken B, Pezzutto A, and Westermann J (2015). *Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma.* **Immunology Letters** 168:260–267.
- 2015 Ostendorf BN, Blau O, Uharek L, Blau IW, and Penack O (2015). *Association between low uric acid levels and acute graft-versus-host disease.* **Annals of Hematology** 94:139–144.
- 2013 Gödel M*, Ostendorf BN*, Baumer J, Weber K, and Huber TB (2013). *A novel domain regulating degradation of the glomerular slit diaphragm protein podocin in cell culture systems.* **PLOS ONE** 8:e57078. (*equal contribution)

Reviews, chapters, and comments

- 2020 Ostendorf BN[†] and Tavazoie SF[†] (2020). *Autophagy suppresses breast cancer metastasis.* **Developmental Cell** 52:542–544. ([†]corresponding authors)
- 2016 Ostendorf BN, Hansmann L, Ludwig WD, Dörken B, Ratei R, and Westermann J (2016). *[Flow-cytometric immunophenotyping in clinical diagnostics].* **Dtsch Med Wochenschr** 141:1569–1574.
- 2014 Ostendorf BN[†], Coutre P le, Kim TD, and Quintás-Cardama A (2014). *Nilotinib. Recent results in cancer research* 201:67–80. ([†]corresponding author)
- 2013 Ostendorf BN (2013). *[Hematological neoplasias].* In: *Meditorium Podcasts.* Ed. by L Graaf and S Ewert.

Case reports

- 2015 Ostendorf BN[†], Nogai H, Baldus CD, Burmeister T, and Arnold R (2015). *Bcr-abl mutation-guided therapy for CML blast crisis: a case report.* **Biomarker insights** 10:25–28. ([†]corresponding author)
- 2015 Ostendorf BN[†], Terwey TH, Hemmati PG, Böhmer D, Pleyer U, and Arnold R (2015). *Severe radiotoxicity in an allogeneic transplant recipient with a heterozygous ATM mutation.* **European Journal of Haematology** 95:90–92. ([†]corresponding author)
- 2014 Ostendorf BN[†], Jehn CF, Vuong LG, Nogai H, Hemmati PG, Gebauer B, Penack O, Blau IW, Anagnostopoulos I, and Arnold R (2014). *Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report.* **SpringerPlus** 3:278. ([†]corresponding author)

- 2011 Ostendorf BN, Oehler RL, and Greene JN (2011). *Human staphylococcus intermedius infection in a patient with postradiation changes.* **Infectious Diseases in Clinical Practice** 19:426–427.

PD Dr. med. Benjamin Ostendorf, PhD
Berlin, March 14, 2024